Table 1.

Patients characteristics

MelanomaMelanomaNSCLCColorectal cancer
BRAF V600-mutated (n = 18)Not mutated for BRAF V600 (n = 23)KRAS-mutated (n = 24)KRAS-mutated (n = 30)
CharacteristicsNumber (%)Number (%)Number (%)Number (%)
Age, years [median (range)]47 (20–47)55 (29–80)55 (44–69)57 (36–86)
Weight, kg (median (range)]71 (52–94)67 (51–98)67 (45–102)70.5 (43–166)
Sex (male/female)7/11 (39/61)10/13 (43/57)5/19 (21/79)14/16 (47/53)
Race (White/Black)18/0 (100/0)23/0 (100/0)24/0 (100/0)29/1 (97/3)
ECOG baseline
 0/1/2/NK10/8/0/0 (56/44/0/0)16/7/0/0 (70/30/0/0)7/14/1/2 (30/58/4/8)13/16/0/1 (43/54/0/3)
Number of metastatic sites
 0/1/2/≥30/2/2/14 (0/11/11/78)0/2/6/15 (0/9/26/65)1/1/5/17 (4/4/21/71)0/2/13/15 (0/7/43/50)
Previous brain metastases3 (17)0 (0)6 (2500 (0)
Prior anticancer treatments
 Surgery17 (94)18 (78)8 (33)24 (80)
 Radiation8 (44)11 (48)11 (46)5 (17)
Prior systemic therapiesa
 0/1/2/≥36/4/4/4 (33/22/22/22)5/7/10/1 (22/30/43/4)0/2/12/10 (0/8/50/42)0/1/24/5 (0/3/80/17)
 Previous BRAF inhibitor2 (11)1 (4)0 (0)0 (0)
 Previous anti-CTLA4 antibodyb5 (28)3 (13)0 (0)0 (0)

Abbreviation: NK, not known.

  • aIncluding prior chemotherapy and/or immunotherapy and/or targeted agents.

  • bDefined as previous therapy with ipilimumab or tremelimumab.